Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
Completed
Phase 3 ResultsSummary of Purpose
To determine the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with atrial fibrillation without rheumatic heart disease.
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 26 April 2012.
| 1 Jul 1985 | 27 Oct 1999 | Unavailable | 1 Jun 1991 | 1 Apr 2012 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Allocation: Randomized
- Purpose: Prevention
Contacts
Not available
Recruitment
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
Principal Investigator
-
Dr. J. Philip Kistler
Stroke Service, Massachusetts General Hospital, Boston MA.
Locations
- U.S.
